Frédéric Revah



Immediately prior to joining [Généthon] in January 2010, Frédéric Revah had been Chief Executive Officer of the oncology start-up Sepal Pharma since 2008. Before that, he had served as Vice President, Drug Discovery, and Chief Scientific Officer Director at the NYSE Euronext-listed biotech company Cerep from 1999 to 2007 and Chief Executive Officer of its oncology subsidiary.

At Cerep, Frédéric Revah had worldwide responsibility for the company's R&D platform (250 researchers and technicians) and took several molecules into the clinic. Prior to his time at Cerep, Frédéric Revah was Head of the Gene Therapy Department in the Central Nervous System and Neurochemistry Department at Rhône Poulenc Rorer (now Sanofi-Aventis) from 1992 to 1998.

Frédéric started his career as an associate staff researcher at the Pasteur Institute (from 1990 to 1992). He obtained his doctorate at the Pasteur Institute/University of Paris V in 1991 and is a graduate (1985) of the elite Ecole Polytechnique engineering school. Frédéric Revah has co-authored 35 scientific publications in prestigious international journals, including Nature, Nature Medicine, Proceedings of the National Academy of Sciences of the USA

Frédéric Revah has served as an advisor to several private and public sector organizations, including the French National Scientific Research Center's laboratory evaluation committee and the Scientific Advisory Board at Edmond de Rothschild Investment Partners.

Call 0033 1-69-47-12-85